Abstract Number: 944 • 2012 ACR/ARHP Annual Meeting
Job-Related Burden and Effort-Reward Imbalance in Patients with Systemic Lupus Erythematosus
Background/Purpose: Working life factors influence patients’ (life) satisfaction and well being. Effort at work is part of a social contract that reciprocates effort by adequate…Abstract Number: 1710 • 2012 ACR/ARHP Annual Meeting
Increase in Vitamin D Improves Disease Activity and Systolic Blood Pressure in Systemic Lupus Erythematosus
Background/Purpose: Vitamin D deficiency has also been associated with different chronic conditions including cardiovascular diseases such as coronary artery disease, cardiac failure and hypertension. In…Abstract Number: 932 • 2012 ACR/ARHP Annual Meeting
Medical Costs and Health Care Resource Use in Patients with Systemic Lupus Erythematosus in an Insured Population
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that may affect multiple organ systems. The clinical manifestations of SLE are heterogeneous, and subjects…Abstract Number: 1427 • 2012 ACR/ARHP Annual Meeting
Late Onset Systemic Lupus Erythematosus: Is It Actually A Milder Variant?
Background/Purpose: Classically, late onset Systemic Lupus Erythematosus (SLE) has been described as a milder variant of the disease. The objective of this study is to…Abstract Number: 886 • 2012 ACR/ARHP Annual Meeting
Association Between Neutrophil Gene Signature and Disease Characteristics in Systemic Lupus Erythematosus Patients
Background/Purpose: Neutrophils and neutrophil death (“netosis”) are now understood to play a role in the pathogenesis of SLE. A neutrophil gene signature exists in SLE,…Abstract Number: 1412 • 2012 ACR/ARHP Annual Meeting
Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin in Systemic Lupus Erythematosus
Background/Purpose: Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. High levels of VCAM-1 have been…Abstract Number: 843 • 2012 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 5 Associates with Systemic Lupus Erythematosus Through Two Distinct and Independent Effects
Background/Purpose: Powerful evidence suggests that Systemic lupus erythematous (SLE or lupus) autoimmunity is mediated by disregulation of the IRF5-NFκB signaling pathway. The interferon regulatory factor 5…Abstract Number: 1387 • 2012 ACR/ARHP Annual Meeting
Hospitalizations and Reasons for Admission in a Clinical SLE Cohort
Background/Purpose: Data published from several countries have suggested that patients affected by systemic lupus erythematous (SLE) may have high annual hospitalization rates. However, there is…Abstract Number: 845 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Immune Complexes Upregulate the Expression of CD319 and CD229 On Plasmacytoid Dendritic Cells
Background/Purpose: Patients with SLE have an activated type I interferon (IFN) system due to an ongoing IFN-alpha synthesis by plasmacytoid dendritic cells (pDCs) stimulated by…Abstract Number: 1393 • 2012 ACR/ARHP Annual Meeting
Predictors of Panniculitis in Systemic Lupus Erythematosus
Background/Purpose: Panniculitis is a rare, but devastating manifestation of SLE. We examined associates of panniculitis in a large SLE cohort. Methods: 52 out of 2,149…Abstract Number: 663 • 2012 ACR/ARHP Annual Meeting
The Clinical Significance and Expression of P2X7 Purinergic Receptor in Peripheral Blood from Patients with New-Oneset Systemic Lupus Erythematosus
Background/Purpose: P2X7 purinergic receptor (P2X7R) is encoded by a gene within the human SLE locus SLEB4. Extracellular adenosine triphosphate (ATP) regulates inflammatory cells by activation…Abstract Number: 1395 • 2012 ACR/ARHP Annual Meeting
The Validation of a New Simple Disease Activity Tool in Systemic Lupus Erythematosus (SLE): The Lupus Activity Scoring Tool (LAST) As Compared to the Sledai Selena Modification
Background/Purpose: SLE is a chronic autoimmune disease with variable manifestations. New developments in the understanding and treatment of SLE mandated closer monitoring of the disease…Abstract Number: 633 • 2012 ACR/ARHP Annual Meeting
Missed Work Days in Systemic Lupus Erythematosus
Background/Purpose: Indirect costs are part of the medical and financial burden of SLE. These costs are easy to undervalue because a significant portion of this…
